NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
Neuronetics (NASDAQ: STIM) is partnering with non-profit This Is My Brave for Teen Mental Health Month in August. The initiative aims to raise awareness and provide resources for teen mental health amidst rising concerns. Over 40% of high school students report feelings of sadness or hopelessness, and nearly 70% of adolescents felt a negative impact on their mental health due to the COVID-19 pandemic.
The partnership focuses on equipping teens and communities with information and skills to navigate mental health challenges. It also advocates for the official recognition of August as Teen Mental Health Month. NeuroStar TMS Therapy is now indicated for treating depression in adolescents aged 15 and older, demonstrating Neuronetics' commitment to teen mental health.
Statistics highlight the urgency: suicide is the third leading cause of death among high school-aged youths, and 50% of mental illnesses begin by age 14. The partnership aims to address these issues and improve adolescent mental health outcomes through innovative treatment and awareness.
Neuronetics (NASDAQ: STIM) sta collaborando con l'organizzazione non profit This Is My Brave per il Mese della Salute Mentale degli Adolescenti in agosto. L'iniziativa ha l'obiettivo di aumentare la consapevolezza e fornire risorse per la salute mentale degli adolescenti in un contesto di preoccupazioni crescenti. Oltre il 40% degli studenti delle scuole superiori riporta sensazioni di tristezza o disperazione, e quasi il 70% degli adolescenti ha subito un impatto negativo sulla propria salute mentale a causa della pandemia di COVID-19.
La partnership si concentra sulla fornitura di informazioni e competenze agli adolescenti e alle comunità per affrontare le sfide della salute mentale. Propone anche il riconoscimento ufficiale di agosto come Mese della Salute Mentale degli Adolescenti. NeuroStar TMS Therapy è ora indicato per il trattamento della depressione negli adolescenti di 15 anni e oltre, dimostrando l'impegno di Neuronetics verso la salute mentale degli adolescenti.
Le statistiche evidenziano l'urgenza della situazione: il suicidio è la terza causa di morte tra i giovani in età di scuola superiore e il 50% delle malattie mentali inizia entro i 14 anni. La partnership mira ad affrontare queste problematiche e migliorare i risultati della salute mentale degli adolescenti attraverso trattamenti innovativi e sensibilizzazione.
Neuronetics (NASDAQ: STIM) se asocia con la organización sin fines de lucro This Is My Brave para el Mes de la Salud Mental de los Adolescentes en agosto. La iniciativa tiene como objetivo aumentar la conciencia y proporcionar recursos para la salud mental de los adolescentes ante la creciente preocupación. Más del 40% de los estudiantes de secundaria informan sentimientos de tristeza o desesperanza, y casi el 70% de los adolescentes sintieron un impacto negativo en su salud mental debido a la pandemia de COVID-19.
La asociación se centra en dotar a los adolescentes y las comunidades de información y habilidades para enfrentar los desafíos de la salud mental. También aboga por el reconocimiento oficial de agosto como el Mes de la Salud Mental de los Adolescentes. NeuroStar TMS Therapy ahora está indicado para tratar la depresión en adolescentes de 15 años en adelante, demostrando el compromiso de Neuronetics con la salud mental juvenil.
Las estadísticas destacan la urgencia: el suicidio es la tercera causa principal de muerte entre los jóvenes en edad escolar, y el 50% de las enfermedades mentales comienzan antes de los 14 años. La asociación tiene como objetivo abordar estos problemas y mejorar los resultados de salud mental de los adolescentes a través de tratamientos innovadores y concienciación.
Neuronetics (NASDAQ: STIM)은 비영리 단체 This Is My Brave와 협력하여 10대 정신 건강의 달을 8월에 기념합니다. 이 이니셔티브는 증가하는 우려 속에서 청소년 정신 건강에 대한 인식을 높이고 리소스를 제공하는 것을 목표로 합니다. 고등학생의 40% 이상이 슬픔이나 절망감을 느끼고 있으며, 거의 70%의 청소년이 COVID-19 팬데믹으로 인해 정신 건강에 부정적인 영향을 받았다고 보고하고 있습니다.
이 파트너십은 청소년과 지역 사회가 정신 건강 문제를 극복할 수 있도록 정보와 기술을 제공하는 데 중점을 두고 있습니다. 또한 8월을 청소년 정신 건강의 공식적인 달로 인정받기 위해 Advocacy 하고 있습니다. NeuroStar TMS Therapy는 15세 이상의 청소년 우울증 치료에 적합하다고 나타나며, 이는 청소년 정신 건강에 대한 Neuronetics의 헌신을 보여줍니다.
통계는 절실함을 강조합니다: 자살은 고등학생 사망 원인 중 세 번째이며, 정신 질환의 50%가 14세까지 시작됩니다. 이 파트너십은 이러한 문제를 해결하고 혁신적인 치료와 인식을 통해 청소년 정신 건강 결과를 개선하는 것을 목표로 합니다.
Neuronetics (NASDAQ: STIM) s'associe à l'organisation à but non lucratif This Is My Brave pour le Mois de la Santé Mentale des Adolescents en août. L'initiative vise à sensibiliser et à fournir des ressources pour la santé mentale des adolescents face à des préoccupations croissantes. Plus de 40 % des lycéens signalent des sentiments de tristesse ou de désespoir, et près de 70 % des adolescents ont ressenti un impact négatif sur leur santé mentale en raison de la pandémie de COVID-19.
Ce partenariat se concentre sur l'équipement des adolescents et des communautés avec des informations et des compétences pour faire face aux défis de la santé mentale. Il plaide également pour la reconnaissance officielle d'août comme Mois de la Santé Mentale des Adolescents. NeuroStar TMS Therapy est maintenant indiqué pour le traitement de la dépression chez les adolescents âgés de 15 ans et plus, démontrant l'engagement de Neuronetics envers la santé mentale des adolescents.
Les statistiques soulignent l'urgence : le suicide est la troisième cause de décès chez les jeunes du secondaire, et 50 % des maladies mentales apparaissent avant l'âge de 14 ans. Ce partenariat vise à aborder ces problèmes et à améliorer les résultats en matière de santé mentale des adolescents grâce à des traitements innovants et à la sensibilisation.
Neuronetics (NASDAQ: STIM) kooperiert mit der gemeinnützigen Organisation This Is My Brave für den Monat der psychischen Gesundheit von Teenagern im August. Die Initiative zielt darauf ab, das Bewusstsein zu schärfen und Ressourcen für die psychische Gesundheit von Jugendlichen angesichts wachsender Bedenken bereitzustellen. Über 40 % der Schüler berichten von Gefühlen der Traurigkeit oder Hoffnungslosigkeit, und fast 70 % der Jugendlichen fühlen sich durch die COVID-19-Pandemie negativ betroffen.
Die Partnerschaft konzentriert sich darauf, Jugendliche und Gemeinschaften mit Informationen und Fähigkeiten auszustatten, um mit Herausforderungen der psychischen Gesundheit umzugehen. Zudem setzt sie sich für die offizielle Anerkennung des Augusts als Monat der psychischen Gesundheit von Teenagern ein. NeuroStar TMS Therapy ist jetzt zur Behandlung von Depressionen bei Jugendlichen ab 15 Jahren indiziert, was das Engagement von Neuronetics für die psychische Gesundheit von Jugendlichen zeigt.
Statistiken verdeutlichen die Dringlichkeit: Suizid ist die dritthäufigste Todesursache unter Jugendlichen im Schulalter, und 50 % der psychischen Erkrankungen beginnen vor dem 14. Lebensjahr. Die Partnerschaft zielt darauf ab, diese Probleme anzugehen und die Ergebnisse der psychischen Gesundheit von Jugendlichen durch innovative Behandlung und Bewusstsein zu verbessern.
- None.
- None.
New initiative aims to provide information and resources for teen mental health amidst rising public health concerns
MALVERN, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is partnering with non-profit This Is My Brave to raise awareness and provide essential resources to support the mental health and well-being of teens and young adults for Teen Mental Health Month in August.
“More than
NeuroStar and This Is My Brave are united in their efforts to equip adolescents and their communities with the information, resources, and skills to navigate mental health challenges. The Substance Abuse and Mental Health Services Administration (SAMHSA) reports that nearly
“We are grateful to have NeuroStar as a partner in this endeavor. Their dedication to improving adolescent mental health outcomes through innovative treatment and raising awareness of such options aligns seamlessly with our goals for Teen Mental Health Month,” said Erin Gallagher, Executive Director of This Is My Brave. “At This Is My Brave, our goal is to provide a platform for individuals to share their stories and foster understanding of, and support for, mental health challenges.”
According to the Centers for Disease Control and Prevention (CDC), suicide is the third leading cause of death among high school-aged youths aged 15–19 years.3 Additionally, the American Psychiatric Association (APA) indicates that
For more information about This is My Brave and Teen Mental Health Awareness Month, please visit www.thismybrave.org/tmhm. For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.
About This Is My Brave
This Is My Brave was co-founded in Virginia by Jennifer Marshall and Anne Marie Ames (1958-2017), two women passionate about ending the stigma surrounding mental illness and saving lives through storytelling. In May of 2014, TIMB debuted its first ever live show in Arlington, VA, at the Spectrum Theatre to a sold-out crowd of nearly 400. Over the past ten years, the nonprofit organization has hosted 110 performances across the United States and in Australia featuring over 1,000 storytellers. TIMB has been featured in The Washington Post, O, The Oprah Magazine, Stage-Directions Magazine, and Health as well as on the TODAY Show and many local media outlets. In 2019, This Is My Brave debuted their short documentary film and launched high school and college pilot programs, and in 2021 TIMB and Principle Pictures launched Our Turn to Talk, a teen mental health podcast and documentary.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.
About Adolescent Depression
Adolescent depression is a complex and challenging mental health condition that affects young individuals during the crucial period of adolescence. An estimated 4.3 million U.S. adolescents aged 15-21 are affected by MDD. Depression amongst adolescents can disrupt crucial aspects of development, such as academic performance, relationships with peers and family members, and overall emotional well-being.
NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of MDD in adolescent patients aged 15-21.
Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
Sources
- Centers for Disease Control and Prevention. (2023). Youth Risk Behavior Surveillance System Data Summary & Trends Report: 2023. Retrieved from https://www.cdc.gov/healthyyouth/data/yrbs/pdf/YRBS_Data-Summary-Trends_Report2023_508.pdf
- Substance Abuse and Mental Health Services Administration. (2021). 2020 National Survey on Drug Use and Health: The COVID-19 pandemic and substance use. Retrieved from https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf
- Centers for Disease Control and Prevention. (n.d.). Adolescent health. Retrieved July 23, 2024, from https://www.cdc.gov/nchs/fastats/adolescent-health.htm
- American Psychiatric Association. (n.d.). Warning signs of mental illness. Retrieved July 23, 2024, from https://www.psychiatry.org/patients-families/warning-signs-of-mental-illness
FAQ
What is Neuronetics (STIM) doing for Teen Mental Health Month in August 2024?
How has NeuroStar TMS Therapy expanded its treatment options for teens?
What percentage of high school students report feelings of sadness or hopelessness according to the PR?
How did the COVID-19 pandemic impact adolescent mental health according to SAMHSA?
What is the goal of This Is My Brave in relation to teen mental health?
